We aim for sustainable performance over time to benefit patients, employees, shareholders and society. Solid financial results and maintaining the trust of society underpin our ability to create value.
Scientists working in lab.

R&D Investor Event 2023

November 28, 2023 | London, UK
 

Read the media release

Watch the webcast

Access our interactive presentation (PDF 17 MB)
 

Walkway at the entrance of the Novartis Campus in Basel, Switzerland

Investors Event Calendar

View recent presentations and learn more about upcoming events.
 
January 08, 2024
J.P. Morgan Healthcare Conference
San Francisco, USA
 

Learn more
Scientist in the lab

Third quarter results 2023

October 24, 2023 | Basel, Switzerland
Media release:
English (PDF 0.4 MB) | Deutsch (PDF 0.4 MB) | Français (PDF 0.5 MB)

Interim financial report (PDF 0.6 MB)

Watch the webcast

Download the podcast (MP3 33 MB)

Download the interactive presentation (PDF 3.5 MB)

Novartis Q3 2023 Impact and Sustainability Update (PDF 1.0 MB)

Learn more
Doctor prescribing medication in Rwanda

Environmental, Social and Governance (ESG)

Novartis aims to hold itself to the highest standards of sustainability and ethical business practices. We take bold steps to increase access to medicines, tackle complex global health challenges, and do our part as a responsible corporate citizen.

Learn more

ESG Updates: November 2023 (PDF 1.0 MB) | August 2023 (PDF 0.3 MB) | May 2023 (PDF 1.9 MB) | February 2023 (PDF 0.9 MB)
Latest updates: Impact & Health Equity (PDF 9.9 MB) | Novartis Enterprise Risk Management (PDF 0.2 MB)  | Materiality Assessment


We have created a set of environmental, social and governance indices to signpost where our key disclosures can be found across our publications and channels. Novartis aims to report comprehensively and transparently for all stakeholders concerned with ESG topics.

Explore the ESG indices
Stocks
Van Lacour, prostate cancer patient living in Natchez, Louisiana, who received a Novartis radioligand therapy

Novartis Annual Reporting Suite

Read and download our integrated report, annual regulatory filings, and other disclosures.

Learn more

Media Releases

Dec 08, 2023

  • Media Release

Latest Novartis Kisqali® NATALEE analysis reinforces 25% reduction in risk of recurrence across broad population of patients with early breast cancer; supports regulatory submissions

Dec 06, 2023

  • Media Release

Novartis receives FDA approval for Fabhalta® (iptacopan), offering superior hemoglobin improvement in the absence of transfusions as the first oral monotherapy for adults with PNH

Nov 28, 2023

  • Media Release

Novartis upgrades mid-term sales growth guidance, showcases its differentiated innovative medicines strategy and robust pipeline at R&D Day
All media releases

Pulse Updates

Apr 21, 2023

  • Pulse Update

FDA approves Novartis Millburn facility for US commercial production of Pluvicto®

Mar 02, 2023

  • Pulse Update

Novartis completes FDA filing for approval of Millburn facility to support Pluvicto® launch

Jan 09, 2023

  • Pulse Update

Novartis shares strategy insights and highlights key pipeline catalysts at JP Morgan Healthcare Conference 2023
View all pulse updates

Investor Relations Contacts

For questions about investor relations or the share registry, please contact our team.

Stay Up-to-Date

Stay connected to the latest news and information from Novartis.

 

Novartis AG
Lichtstrasse 35
CH-4056 Basel, Switzerland